arzoxifene

DRUG6 trials

Sponsors

University of Kansas Medical Center, Eli Lilly and Company

Conditions

Breast CancerEndometrial CancerOsteoporosisOsteoporosis, PostmenopausalOvarian CancerPostmenopausal Bone Loss

Phase 2

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

CompletedNCT00005879

University of Kansas Medical CenterBreast Cancer

Start: 2000-08-31End: 2008-07-31Updated: 2017-05-30

A Study of Arzoxifene to Treat Korean Women With Osteoporosis

CompletedNCT00767299

Eli Lilly and CompanyOsteoporosis

Start: 2008-12-31End: 2009-10-31Updated: 2015-04-30

Phase 3

Effects of Arzoxifene on Bone Mass and the Uterus

CompletedNCT00085956

Eli Lilly and CompanyPostmenopausal Bone Loss

Start: 2004-04-30End: 2007-02-28Target: 300Updated: 2007-03-09

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

CompletedNCT00088010

Eli Lilly and CompanyOsteoporosis, Postmenopausal

Start: 2004-06-30End: 2009-11-30Updated: 2010-06-02

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

CompletedNCT00383422

Eli Lilly and CompanyOsteoporosis, Postmenopausal

Start: 2006-10-31End: 2008-07-31Updated: 2010-01-28

Phase 4

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

CompletedNCT00190697

Eli Lilly and CompanyBreast Cancer, Endometrial Cancer, Ovarian Cancer

Start: 2001-01-31End: 2007-04-30Target: 70Updated: 2007-05-25

Related Papers

Association of back pain with hypovitaminosis D in postmenopausal women with low bone mass

BMC Musculoskeletal Disorders2013-06-1231 citations